<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02884791</url>
  </required_header>
  <id_info>
    <org_study_id>2015P000381</org_study_id>
    <nct_id>NCT02884791</nct_id>
  </id_info>
  <brief_title>FGF21 and Fructose Challenge in Humans</brief_title>
  <official_title>Fibroblast Growth Factor 21 and Fructose Challenge in Humans</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beth Israel Deaconess Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beth Israel Deaconess Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary aim of this study is to examine the effect of acute ingestion of fructose on
      serum FGF21 levels. Subjects in this study will be lean volunteers and individuals with
      metabolic syndrome.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Participation in this study involves fasting overnight, drinking a sweet beverage, and
      several blood draws through an IV line. Each subject may drink up to 10 different sweet
      beverages, separated by 2 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2016</start_date>
  <completion_date type="Anticipated">February 2019</completion_date>
  <primary_completion_date type="Anticipated">August 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Fibroblast Growth Factor 21 levels in human serum</measure>
    <time_frame>5 hours</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Fasting</condition>
  <arm_group>
    <arm_group_label>Fasting (Healthy)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participation in this study involves fasting overnight, drinking a sweet beverage, and several blood draws through an IV line. Each subject may drink up to10 different sweet beverages, separated by 2 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fasting (metabolic syndrome)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participation in this study involves fasting overnight, drinking a sweet beverage, and several blood draws through an IV line. Each subject may drink up to10 different sweet beverages, separated by 2 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>oral carbohydrate challenge</intervention_name>
    <description>Participants will fast for 8 hours and then drink a beverage containing fructose.</description>
    <arm_group_label>Fasting (Healthy)</arm_group_label>
    <arm_group_label>Fasting (metabolic syndrome)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria for lean subjects:

          -  Men and women ages 18-60

          -  BMI 19-25 kg/m2; 19-23 for Asian subjects

          -  Stable weight (variation &lt; 3 kg within 6 months of screening visit)

          -  Ability to give informed consent

          -  Ability to follow verbal and written instructions in English

          -  Use of medically approved form of contraception (monophasic oral contraception, intra
             uterine device, surgical sterilization or 2 combined barrier methods)

        Specific exclusion criteria for lean subjects:

          -  Fasting blood glucose &gt;100; 2 hr OGTT blood glucose &gt;140

          -  Fasting triglycerides &gt;150

        Inclusion criteria for metabolic syndrome subjects:

        3 or more of the following (based on joint scientific statement by Alberti et al, 2009:

          -  Fasting triglycerides &gt;150 mg/dl (or on treatment for elevated triglycerides)

          -  HDL cholesterol &lt;40 mg/dl in men or &lt;50 mg/dl in women

          -  Blood pressure &gt; 130/85 (or antihypertensive treatment in a subject with history of
             hypertension)

          -  Fasting BG &gt;100

          -  Elevated waist circumference ** see below for race and ethnic specifications

        Men Women

          -  Asian or Central, South or Native American &gt; 90 cm &gt; 80 cm

          -  Non-Asian, Non-Latino United States &gt; 102 cm &gt; 88 cm

        General Exclusion criteria

          -  Type 1 or type 2 diabetes mellitus diagnosed according to American Diabetes
             Association criteria

          -  Coronary heart disease (history of myocardial infarction, unstable angina pectoris, or
             congestive heart failure)

          -  Uncontrolled hypertension (BP &gt; 160/100 mmHg on or off antihypertensive medication)

          -  Marijuana or intravenous drug use

          -  Recent weight loss (&gt; 3 kg within 6 months of the screening visit)

          -  Gastroparesis

          -  Inflammatory or irritable bowel disease

          -  Malignancy treated with chemotherapy within the past 3 years

          -  Depression or psychosis requiring hospitalization

          -  Renal insufficiency (creatinine clearance &lt; 40 ml/min)

          -  Transaminases &gt; 2x above the normal range

          -  Known liver disease

          -  Pregnancy within 6 months of the screening visit

          -  Lactation

          -  Failure to use medically approved contraceptive methods

          -  History of surgery for the treatment of obesity (gastric banding, gastric bypass,
             gastric stapling)

          -  Change in dose of thyroid hormone or antithyroidal medication within 3 months of
             screening visit

          -  History of alcohol abuse within the past 5 years

          -  Fructose intolerance

        Exclusionary medications:

          -  Oral steroids

          -  Metformin

          -  Weight loss medications including nonprescription supplements
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jody Dushay, MD</last_name>
    <phone>617-667-1793</phone>
    <email>jdushay@bidmc.harvard.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jody Dushay, MD</last_name>
      <phone>617-667-1793</phone>
      <email>jdushay@bidmc.harvard.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 23, 2016</study_first_submitted>
  <study_first_submitted_qc>August 26, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2016</study_first_posted>
  <last_update_submitted>March 5, 2018</last_update_submitted>
  <last_update_submitted_qc>March 5, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 7, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beth Israel Deaconess Medical Center</investigator_affiliation>
    <investigator_full_name>Jody Dushay</investigator_full_name>
    <investigator_title>Assistant Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>FGF21</keyword>
  <keyword>Fibroblast growth factor</keyword>
  <keyword>fructose</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

